Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery Disease

Abstract

Background and objectives: Peripheral artery disease (PAD) is common in patients on hemodialysis (HD).

Impact of diabetes and glycaemic control on peripheral artery disease in Japanese patients with end-stage renal disease: long-term follow-up study from the beginning of haemodialysis

“…Although adequately powered clinical trials on such medications in haemodialysis patients are still needed, it seems likely that intensive medical intervention might improve the prognosis in haemodialysis patients with diabetes mellitus and/or poor glycaemic control. Indeed, we have already reported the effectiveness of cilostazol in haemodialysis patients with PAD, although the data reported on were retrospective [30].…”

Drug-Coated Balloon vs. Conventional Balloon Angioplasty in Dialysis Patients With Symptomatic Femoropopliteal Disease ― A Matched Comparison ―

“…31- 33 In patients with femoropopliteal disease who have undergone EVT, treatment with cilostazol is associated with a significant reduction of CD-TLR and in-stent restenosis, 34,35 as well as an improvement of long-term patency in dialysis patients after EVT. 36 Our study demonstrated a beneficial effect of cilostazol in reducing binary restenosis in dialysis patients after EVT, possibly because of the vasodilatory, antiinflammatory and antiproliferative effects on vascular smooth muscle cells. However, cilostazol administration did not appear to improve the CD-TLR-free rate in this study.…”

Cilostazol Prevents Progression of Asymptomatic Carotid Artery Stenosis in Patients with Contralateral Carotid Artery Stenting

“…Several recent studies reported that cilostazol reduced restenosis and repeat revascularization after coronary intervention with either a bare-metal stent or a drug-eluting stent. 20,22,26,49,50 Similarly, cilostazol reduced restenosis after endovascular therapy in peripheral arteries, [15][16][17][18] and some studies reported the effectiveness of cilostazol in the prevention of restenosis after CAS. In 1 study, restenosis during a 29-month period after CAS occurred in none (0/ 27) of the patients who received cilostazol and in 15.7% (11/70) of patients who did not receive cilostazol.…”

“…14 In patients with coronary and peripheral artery disease, cilostazol has been shown to decrease restenosis and revascularization after catheter intervention. [15][16][17][18][19][20][21][22][23][24][25][26] Furthermore, some previous reports suggested that cilostazol reduced restenosis after CEA and CAS.…”